List view / Grid view
AstraZeneca today announced that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...
Abbott announced today CE Marking (Conformité Européenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.
27 August 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM...
27 August 2012 | By Boehringer Ingelheim
40,000 people estimated to be saved from a stroke related to non-valvular atrial fibrillation...
27 August 2012 | By Boehringer Ingelheim
New data to be presented at the Annual Congress of the ERS 2012...
27 August 2012 | By Roche
Pivotal study met co-primary efficacy endpoint of overall survival...
26 August 2012 | By Eli Lilly and Company
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population...
26 August 2012 | By Merck
Merck provided an update on the development programs for vorapaxar, extended release niacin/laropirprant and anacetrapib...
26 August 2012 | By Novartis
Novartis announced results from the Phase II PARAMOUNT study...
24 August 2012 | By GlaxoSmithKline
GSK confirms its intention to commence global filings from the end of 2012...
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
23 August 2012 | By GlaxoSmithKline
“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.”
22 August 2012 | By Daiichi Sankyo
Inavir® Dry Powder Inhaler significantly reduces the incidence of influenza infection...
22 August 2012 | By H. Lundbeck A/S
Lundbeck has appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president...
